Passive Immunotherapies Protect WRvFire and IHD-J-Luc Vaccinia Virus-Infected Mice from Lethality by Reducing Viral Loads in the Upper Respiratory Tract and Internal Organs
- 1 September 2011
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 85 (17) , 9147-9158
Abstract
Whole-body bioimaging was employed to study the effects of passive immunotherapies on lethality and viral dissemination in BALB/c mice challenged with recombinant vaccinia viruses expressing luciferase. WRvFire and IHD-J-Luc vaccinia viruses induced lethality with similar times to death following intranasal infection, but WRvFire replicated at higher levels than IHD-J-Luc in the upper and lower respiratory tracts. Three types of therapies were tested: licensed human anti-vaccinia virus immunoglobulin intravenous (VIGIV); recombinant anti-vaccinia virus immunoglobulin (rVIG; Symphogen, Denmark), an investigational product containing a mixture of 26 human monoclonal antibodies (HuMAbs) against mature virion (MV) and enveloped virion (EV); and HuMAb compositions targeting subsets of MV or EV proteins. Bioluminescence recorded daily showed that pretreatment with VIGIV (30 mg) or with rVIG (100 μg) on day -2 protected mice from death but did not prevent viral replication at the site of inoculation and dissemination to internal organs. Compositions containing HuMAbs against MV or EV proteins were protective in both infection models at 100 μg per animal, but at 30 μg, only anti-EV antibodies conferred protection. Importantly, the t statistic of the mean total fluxes revealed that viral loads in surviving mice were significantly reduced in at least 3 sites for 3 consecutive days (days 3 to 5) postchallenge, while significant reduction for 1 or 2 days in any individual site did not confer protection. Our data suggest that reduction of viral replication at multiple sites, including respiratory tract, spleen, and liver, as monitored by whole-body bioluminescence can be used to predict the effectiveness of passive immunotherapies in mouse models.Keywords
This publication has 38 references indexed in Scilit:
- Capturing the Natural Diversity of the Human Antibody Response against Vaccinia VirusJournal of Virology, 2011
- Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of CongoProceedings of the National Academy of Sciences, 2010
- Repulsion of Superinfecting Virions: A Mechanism for Rapid Virus SpreadScience, 2010
- Application of Bioluminescence Imaging to the Prediction of Lethality in Vaccinia Virus-Infected MiceJournal of Virology, 2009
- Vaccinia Virus Extracellular Enveloped Virion Neutralization In Vitro and Protection In Vivo Depend on ComplementJournal of Virology, 2009
- Differential Antigen Requirements for Protection against Systemic and Intranasal Vaccinia Virus Challenges in MiceJournal of Virology, 2008
- Redundancy and Plasticity of Neutralizing Antibody Responses Are Cornerstone Attributes of the Human Immune Response to the Smallpox VaccineJournal of Virology, 2008
- Vaccinia Virus Entry into Cells via a Low-pH-Dependent Endosomal PathwayJournal of Virology, 2006
- Isolation of Human Antibody Repertoires with Preservation of the Natural Heavy and Light Chain PairingJournal of Molecular Biology, 2006
- Development of a Novel Vaccinia‐Neutralization Assay Based on Reporter‐Gene ExpressionThe Journal of Infectious Diseases, 2003